ZIOPHARM Oncology

NASDAQ: ZIOP
$2.28
-$0.11 (-4.6%)
Closing price April 3, 2020
Four pharmaceutical makers posted new 52-week lows Tuesday: Ohr Pharma, Axovant Sciences, Axsome Therapeutics, and Ziopharm Oncology.
Paul Ausick
The top analyst upgrades, downgrades and other research calls seen on Thursday include Analog Devices, BP, First Data, General Electric, Goodyear, Illinois Tool Works, NRG Energy and Palo Alto...
Jon C. Ogg
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Eldorado Gold, SLM, SunPower, Disney, Yelp and Myriad Genetics.
Jon C. Ogg
July 25, 2016: Here are four stocks trading with heavy volume among 18 equities making new 52-week lows in Monday’s session. NYSE decliners led advancers by about 2 to 1 and Nasdaq decliners...
Paul Ausick
July 22, 2016: Here are three stocks trading with heavy volume among 13 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by about 2 to 1 and Nasdaq advancers...
Paul Ausick
July 19, 2016: Here are four stocks trading with relatively heavy volume among 16 equities making new 52-week lows in Tuesday’s session. NYSE decliners led advancers by about 3 to 2 and Nasdaq...
Paul Ausick
Even though the market made incredible gains this past week, a few companies held it back from pushing even higher.
Chris Lange
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Chris Lange
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Chris Lange
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
Chris Lange
If you missed the biotech run and want to try to catch the train this late in the game, it would be wise not to use the new Proshares leveraged biotech ETFs.
Rafi Farber
The stock market continues to act like an aging prize fighter, one that will not give up despite all the haymakers landed. In keeping with the bullish tone, insiders continue buying stock.
Lee Jackson
When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was due to trading factors and sentiment.
Chris Lange
Source: ThinkstockIntrexon Corp. has filed its paperwork with the Securities and Exchange Commission to allow the company to come public in an initial public offering. No formal financial terms have...
Jon C. Ogg